NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Plotkin SA, Orenstein WA, editors. Vaccines. 3rd edition. Philadelphia: Saunders; 1999.

Cover of Vaccines

Vaccines. 3rd edition.

Show details

Chapter 6References

and .

Author Information
1.
World Health Organization. The global eradication of smallpox. Final report of the global commission for the certification of smallpox eradication. In History of International Public Health No. 4. Geneva, World Health Organization, 1980. (pdf)
2.
de Korte W E. Amaas or kaffir milk-pox. Lancet. 1904;1:1273–1276.
3.
Chapin C V. Variation in type of infectious disease as shown by the history of smallpox in the United States 1895–1912. Infect Dis. 1913;13:171–196.
4.
Fenner F, Henderson DA, Arita I, et al. Smallpox and Its Eradication. Geneva, World Health Organization, 1988. (Book)
5.
McNeill WH. Plagues and People. Garden City, NY, Anchor Press/Doubleday, 1976.
6.
Ruffer MA. Pathological note on the royal mummies of the Cairo Museum. In Moodie RL (ed). Studies in the Paleopathology of Egypt. Chicago, University of Chicago Press, 1921, pp 175-176.
7.
Hopkins DR. Princes and Peasants. Smallpox in History. Chicago, University of Chicago Press, 1983.
8.
Rhazes (Al-Razi, Abu Bakr Muhammad ibn Zakariya). De Variohs et Morbillis Commentarius. Londini, G Bowyer, 1766. English translation: Med Class 4:22–84, 1939.
9.
Dixon CW. Smallpox. London, Churchill, 1962. (pdf)
10.
Moore J. The History of the Smallpox. London, Longman, Hurst, Rees, Orme & Brown, 1815.
11.
Creighton C. History of Epidemics in Britain. Cambridge, Cambridge University Press, 1894. Reprinted London, Cass, 1965.
12.
Macgowan DJ. Report on the health of Wenchow for the half-year ended 31 March 1884. China, Imperial Maritime Customs Medical Reports 27:9–18, 1884.
13.
Needham J. China and the origins of immunology. Centre of Asian Studies Occasional Papers and Monographs No. 41, University of Hong Kong, 1980.
14.
Miller G. Putting Lady Mary in her place: A discussion of historical causation. Bull Hist Med. 1981;55:2–16. [PubMed: 7011451]
15.
Jenner E. An Inquiry into the Causes and Effects of the Variolae Vaccinae, a Disease Discovered in Some of the Western Counties of England. Particularly Gloucestershire and Known by the Name of the Cow Pox. London, 1798. Reprinted in Camac CNB (ed). Classics of Medicine and Surgery. New York, Dover, 1959.
16.
Pasteur L. Vaccination in relation to chicken-cholera and splenic fever. Transactions of the International Medical Congress; Seventh Session; London; August 29, 1881, 1:85–90. Reproduced in Vallery-Radot P (ed). Oeuvres de Pasteur. Vol. 6. Paris, Masson, 1933, pp 370–378.
17.
LeFanu W. A Bio-Bibliography of Edward Jenner 1749–1823. London, Harvey & Blythe, 1951.
18.
del Castillo FF. Los Viajes de Don Francisco Xavier de Balmis. Mexico, Galas de Mexico, 1960.
19.
Bowers J Z. The odyssey of smallpox vaccination. Bull Hist Med. 1981;55:17–33. [PubMed: 7011450]
20.
Nott J C. Smallpox epidemic in Mobile during the winter of 1865–6. Nashville J Med Surg. 1867;2:372–380.
21.
Creighton C. The Natural History of Cow-Pox and Vaccinal Syphilis. London, Cassell, 1887.
22.
Baxby D. The origins of vaccinia virus. J Infect Dis. 1977;136:453–455. [PubMed: 198484]
23.
The History of Inoculation and Vaccination. London, Burroughs Wellcome Company, 1913.
24.
Edwardes EJ. A Concise History of Small-Pox and Vaccination in Europe. London, Lewis, 1902.
25.
Galbiati G. Memoria Sulla Inoculazione Vaccina coll'Umore Ricavato Immediatement dalla Vacca Precedentemente Inoculata. Napoli, 1810.
26.
Congrès Medical de Lyon. Compterendu des travaux et des discussions. Gazette Med Lyon 19:449–47 1, 1864.
27.
Dudgeon J A. Development of smallpox vaccine in England in the eighteenth and nineteenth centuries. BMJ. 1963;1:1367–1372. [PMC free article: PMC2124036] [PubMed: 20789814]
28.
Otten L. Trockenlymphe. Z_Hyg Infektioskrankh. 1927;107:677–696.
29.
Fasquelle R, Fasquelle A. A propos de l’histoire de la lutte contre la variole dans lees pays d’Afrique francophone. Bull Soc Pathol Exot Filiales. 1971;64:734–756. [PubMed: 4949408]
30.
Collier L H. The development of a stable smallpox vaccine. J Hyg (Lond). 1955;53:76–101. [PMC free article: PMC2217800] [PubMed: 14367805]
31.
Pan American Sanitary Organization. Final Reports of the First Second and Third Meetings of the Directing Council. Publication No. 247. Washington, DC, Pan American Sanitary Organization, 1950.
32.
World Health Organization. Eradication of Smallpox. Official Records of the World Health Organization No. 87. Geneva, World Health Organization, 1958, pp 263–264, 508–512.
33.
World Health Organization. Smallpox Eradication. Official Records of the World Health Organization No. 95. Geneva, World Health Organization, 1959, pp 572–588.
34.
World Health Organization. Official Records of the World Health Organization No. 152. Geneva, World Health Organization, 1966, p 291.
35.
World Health Organization. Handbook for Smallpox Eradication in Endemic Areas. Geneva, World Health Organization, 1967.
36.
Henderson D A. The eradication of smallpox. Sci Am. 1976;235:25–33. [PubMed: 788150]
37.
Henderson D A. A discussion on technologies for rural health. Smallpox eradication. Proc R Soc Lond B Biol Sci. 1977;199:83–97. [PubMed: 21417]
38.
Henderson DA The Deliberate Extinction of a Species. Philadelphia, American Philosophical Society, 1982. [PubMed: 11611132]
39.
Deria A, Jezek Z, Markvart K. et al. The world's last endemic case of smallpox: Surveillance and containment measures. Bull World Health Organ. 1980;58:279–283. [PMC free article: PMC2395794] [PubMed: 6967365]
40.
Shooter RA. Report of the Investigation into the Cause of the 1978 Birmingham Smallpox Occurrence. London, Her Majesty's Stationery Office, 1980. (pdf)
41.
Basu RN, Jezek Z, Ward NA. The eradication of smallpox from India. In History of International Public Health No. 2. New Delhi, World Health Organization, South-East Asia Regional Office, 1979.
42.
Brilliant LB. The Management of Smallpox Eradication in India. A Case Study and Analysis. Ann Arbor, University of Michigan Press, 1985.
43.
Joarder AK, Tarantola D, Tulloch J. The Eradication of Smallpox from Bangladesh. World Health Organization Regional Publications South-East Asia Series No. 8. New Delhi, World Health Organization South-East Asia Regional Office, 1980.
44.
Tekeste Y, Hailu A, do Amaral C, et al. Smallpox Eradication in Ethiopia. Brazzaville, World Health Organization, 1984.
45.
Jezek Z, AlAghbari M, Hatfield R, et al. Smallpox Eradication in Somalia. Alexandria, World Health Organization Eastern Mediterranean Regional Office and Ministry of Health, Somali Democratic Republic, 1981.
46.
Nakano JH. Human poxvirus diseases. In Lennette EH (ed). Laboratory Diagnosis of Viral Infections. New York, Marcel Dekker, 1985, pp 401–423.
47.
Hahon N. Cytopathogenicity and propagation of variola virus in tissue culture. J Immunol. 1958;81:426–32. [PubMed: 13598925]
48.
Pirsch J B, Mika L A, Purlson E H. Growth characteristics of variola virus in tissue culture. J Infect Dis. 1963;113:170–178. [PubMed: 14080826]
49.
World Health Organization. Guide to the Laboratory Diagnosis of Smallpox for Smallpox Eradication Programmes. Geneva, World Health Organization, 1969.
50.
Downie A W, St Vincent L, Rao A R, Kempe C H. Antibody response following smallpox vaccination and revaccination. J Hyg (Lond). 1969;67:603–606. [PMC free article: PMC2130769] [PubMed: 4982557]
51.
Downie A W, St Vincent L, Goldstein L. et al. Antibody response in nonhaemorrhagic smallpox patients. J Hyg (Lond). 1969;67:609–618. [PMC free article: PMC2130763] [PubMed: 4982558]
52.
McCarthy K, Downie A W, Bradley W H. The antibody response in man following infection with viruses of the pox group. II. Antibody response following vaccination. J Hyg (Lond). 1958;56:466–478. [PMC free article: PMC2218092] [PubMed: 13611243]
53.
Downie A W, McCarthy K, Macdonald A. et al. Virus and virus antigen in the blood of smallpox patients. Their significances in early diagnosis and prognosis. Lancet. 1978;2:164–166.
54.
White E. Chickenpox in Kerala. Indian J Public Health. 1978;22:141–151. [PubMed: 669759]
55.
Jezek Z, Basu R N, Arya Z S. Problem of persistence of facial pock marks among smallpox patients. Indian J Public Health. 1978;22:95–101. [PubMed: 669769]
56.
Jezek Z, Hardjotanojo W. Residual skin changes in patients who have recovered from variola minor. Bull World Health Organ. 1980;58:139–140. [PMC free article: PMC2395885] [PubMed: 6966543]
57.
Mitra A C, Sarkar J K, Mukheriee M K. Virus content of smallpox scabs. Bull World Health Organ. 1974;51:106–107. [PMC free article: PMC2366245] [PubMed: 4376067]
58.
Anders W, Posch J. Die Pockenausbrucke 1961/62 in Nordrhein-Westfalen. Bundesgesundheitbl. 1962;17:265–269.
59.
Wehrle P F, Posch J, Richter K H, Henderson D A. An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe. Bull World Health Organ. 1970;43:669–679. [PMC free article: PMC2427800] [PubMed: 5313258]
60.
Huq F. Effect of temperature and relative humidity on variola virus in crusts. Bull World Health Organ. 1976;54:710–712. [PMC free article: PMC2366597] [PubMed: 196779]
61.
Harper G J. Airborne micro-organisms: Survival tests with four viruses. J Hyg (Lond). 1961;59:479–486. [PMC free article: PMC2134455] [PubMed: 13904777]
62.
Rogers L. Smallpox and vaccination in British India during the last seventy years. Proc R Soc Lond. 1944;38:135–139. [PMC free article: PMC2181657] [PubMed: 19993010]
63.
Simpson Hope R E. Infectiousness of communicable diseases in the household (measles, chickenpox and mumps). Lancet. 1952;2:549–554. [PubMed: 12981903]
64.
Filho Carvalho E S de, Morris L, de Lemos Lavigne A. et al. Smallpox eradication in Brazil, 1967–69. Bull World Health Organ. 1970;43:797–808. [PMC free article: PMC2427806] [PubMed: 5314627]
65.
Heiner G G, Fatima N, Daniel R W. et al. A study of inapparent infection in smallpox. Am J Epidemiol. 1971;94:252–268. [PubMed: 4999240]
66.
Henderson R H, Yekpe M. Smallpox transmission in southern Dahomey. A study of a village outbreak. Am J Epidemiol. 1969;90:423–428. [PubMed: 5356949]
67.
Thomas D B, McCormack W M, Arita I. et al. Endemic smallpox in rural East Pakistan. I. Methodology, clinical and epidemiologic characteristics of cases, and intervillage transmission. Am J Epidemiol. 1971;93:361–372. [PubMed: 5556397]
68.
Thomas D B, Arita I, McCormack W M. et al. Endemic smallpox in rural East Pakistan. II. Intravillage transmission and infectiousness. Am J Epidemiol. 1971;93:373–383. [PubMed: 4326604]
69.
Thomas D B, Mack T M, Ali A, Khan M M. Epidemiology of smallpox in West Pakistan. III. Outbreak detection and interlocality transmission. Am J Epidemiol. 1972;95:178–189. [PubMed: 5060375]
70.
Foege W H, Millar J D, Henderson D A. Smallpox eradication in west and central Africa. Bull World Health Organ. 1975;52:209–222. [PMC free article: PMC2366358] [PubMed: 1083309]
71.
Sencer DJ, Axnick NW. Cost-benefit analysis. In International Symposium on Vaccination Against Communicable Symposia Series in Immunobiological Standardization 22:37–46, 1973.
72.
Stojkovic L, Birtasevic B, Borjanovic S, et al (eds). Variola u Jugosiaviji 1972 Godine. Ljubljana, CCP Delo, 1974.
73.
Mack T M. Smallpox in Europe, 1950–1971. J Infect Dis. 1972;125:161–169. [PubMed: 5007552]
74.
United Kingdom, Ministry of Health. Report of the Committee on Vaccination. London, His Majesty's Stationery Office, 1928.
75.
Herrlich A, Mayr A, Mahnel H, Munz E. Experimental studies on transformation of the variola virus into the vaccinia virus. Arch Gesamte Virusforsch. 1963;12:579–599. [PubMed: 13954081]
76.
Baxhy D. Jenner's Smallpox Vaccine. The Riddle of the Origin of Vaccinia Virus. London, Heinemann, 1981.
77.
Rivers T M. Cultivation of vaccine virus for Jennerian prophylaxis in man. J Exp Med. 1931;54:453–461. [PMC free article: PMC2132020] [PubMed: 19869932]
78.
Barker LF. Further attenuated vaccinia virus: A possible alternative for primary immunization. In Sixth Annual Immunization Conference; Atlanta, GA; March 11–13, 1969, p 55.
79.
Rivers T M, Ward S M. Jennerian prophylaxis by means of intradermal injections of cultured vaccine virus. J Exp Med. 1935;62:549–560. [PMC free article: PMC2133293] [PubMed: 19870433]
80.
Rivers T M, Ward S M, Baird R D. Amount and duration of immunity induced by intradermal inoculation of cultured vaccine virus. J Exp Med. 1939;69:857–866. [PMC free article: PMC2133758] [PubMed: 19870882]
81.
van der Noordaa J, Dekking F, Posthuma J, Beunders B J W. Primary vaccination with an attenuated strain of vaccinia virus. Arch Gesamte Virusforsch. 1967;22:210–214. [PubMed: 4386851]
82.
Kempe C H, Fulginiti V, Minamitani M, Shinefeld H. Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CV-178). Pediatrics. 1968;42:980–989. [PubMed: 5726388]
83.
Tint H. The rationale for elective prevaccinadon with attenuated vaccine (CV-178) in preventing some vaccination complications. In International Symposium on Smallpox Vaccine. Symposia Series in Immunobiological Standardization. 1973;19:281–292.
84.
Galasso G J, Karzon D T, Katz S L. et al. (eds). Clinical and serological study of four smallpox vaccines comparing variations of dose and route of administration. J Infect Dis. 1977;135:183–186. [PubMed: 833448]
85.
McIntosh K. A comparative study of four smallpox vaccines in children. In Quinnan GV Jr (ed). Vaccinia Viruses as Vectors for Vaccine Antigens. New York, Elsevier, 1985, pp 77–84.
86.
Hochstein-Mintzel V, Hanichen T, Huber H C. et al. Vaccinia-und variolaprotektive Wirkung des modifizierten Vaccinia-Stam-mes MVA bei intramuskularer Immunisierung. Zentralbl Bakteriol Orig A. 1975;230:283–297. [PubMed: 1146441]
87.
Mayr A, Stickl H, Muller H K. et al. The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism. Zentralbl Bakteriol [B] 1978;167:375–390. [PubMed: 219640]
88.
Hashizume S. A new attenuated strain of vaccinia virus, LC 16m8: Basic information [in Japanese] J Clin Virol. 1975;3:229–235.
89.
Hashizume S, Yoshizawa H, Morita M, Suzuki K. Properties of attenuated mutant of vaccinia virus, LC 16m8, derived from Lister strain. In Quinnan GV Jr (ed). Vaccinia Viruses as Vectors for Vaccine Antigens. New York, Elsevier. 1985:87–99.
90.
Kato S. Low neurovirulent variant of Lister strain of vaccinia virus. In Quinnan GV Jr (ed). Vaccinia Viruses as Vectors for Vaccine Antigens. New York, Elsevier, 1985, pp 85–86.
91.
Japan, Ministry of Health . Report of Committee on Smallpox Vaccination. Investigation of treatment of complications caused by smallpox vaccination [in Japanese] Clin Virol. 1975;3:269–278.
92.
Hekker A C, Bos J M, Smith L. A stable freeze-dried smallpox vaccine made in monolayer cultures of primary rabbit kidney cells. J Biol Stand. 1973;1:21–32.
93.
Hekker AC, Huisman J, Polak MF, et al. Field work with a stable freeze-dried vaccine prepared in monolayers of rabbit kidney cells. In International Symposium on Smallpox Vaccine. Symposia Series in Immunobiological standardisation 19:187–195, 1973.
94.
Hekker A C, Bos J M, Kumara N Rai. et al. Large-scale use of freeze-dried smallpox vaccine prepared in primary cultures of rabbit kidney cells. Bull World Health Organ. 1976;54:279–284. [PMC free article: PMC2366578] [PubMed: 1088108]
95.
Cross R M, Kaplan C, McClean D. The heat resistance of dried smallpox vaccine. Lancet. 1957;1:446–448. [PubMed: 13407036]
96.
Downie A W, McCarthy K. The antibody response in man following infection with viruses of the pox group. III. Antibody response in smallpox. J Hyg (Lond). 1958;56:479–487. [PMC free article: PMC2218083] [PubMed: 13611244]
97.
Pincus W B, Flick J A. The role of hypersensitivity in the pathogenesis of vaccinia virus in humans. J Pediatr. 1963;62:57–62. [PubMed: 13943652]
98.
Blattner R J, Norman J O, Heys F M, Aksu I. Antibody response to cutaneous inoculation with vaccinia virus: Viremia and viruria in vaccinated children. J Pediatr. 1964;64:839–852. [PubMed: 14172233]
99.
Gins H A, Hackenthal H, Kamentzewa N. Experimentelle Untersuchungen fiber die Generalisierung des Vaccine-Virus beim Menschen und Versuchstier. Z Hyg Infectionskrankh. 1929;110:429–441.
100.
Benenson A S. Immediate (so-called “immune”) reaction to smallpox vaccination. J Am Med Assoc. 1950;143:1238–1249. [PubMed: 15390369]
101.
WHO Expert Committee on Smallpox. First report. WHO Technical Report Series No. 283. Geneva, World Health Organization, 1964. [PubMed: 14171838]
102.
Hanna W. Studies in Smallpox and Vaccination. Bristol, Wright, 1913.
103.
Rao A.R. Smallpox. Bombay, The Kothari Book Depot, 1972. (pdf)
104.
Zikmund V, Das N, Krishnayengar R, Kameswara B Rao. Contribution to the problem of challenge vaccination. Observations on vaccination of cured smallpox cases in India in 1971, 1972 and 1973. Indian J Public Health. 1978;22:102–106. [PubMed: 669754]
105.
Winter P A, Mason J H, Kuhr E. et al. Combined immunization against poliomyelitis, diphtheria, whooping cough, tetanus and smallpox. S Afr Med J. 1963;37:513–515. [PubMed: 14001253]
106.
Karchmer A W, Friedman J P, Casey H L. et al. Simultaneous administration of live virus vaccines. Measles, mumps, poliomyelitis and smallpox. Am J Dis Child. 1971;121:382–388. [PubMed: 4933290]
107.
Lin H T. A study of the effect of simultaneous vaccination with BCG and smallpox vaccine in newborn infants. Bull World Health Organ. 1965;33:321–336. [PMC free article: PMC2475846] [PubMed: 5294917]
108.
Meers P D. Further observations on 17D-yellow fever vaccination by scarification, with and without simultaneous smallpox vaccination. Transfusion (Paris). 1960;54:493–501. [PubMed: 13768949]
109.
Breman J G, Coffi E, Bomba-Ires K R. et al. Evaluation of a measles-smallpox vaccination campaign by a seroepidemiologic method. Am J Epidemiol. 1975;102:564–571. [PubMed: 173183]
110.
Meyer H M Jr, Hostetler D D Jr, Bernheim B C. et al. Response of Volta children to jet inoculation of combined live measles, smallpox and yellow fever vaccines. Bull World Health Organ. 1964;30:783–794. [PMC free article: PMC2555088] [PubMed: 14215185]
111.
Ruben F L, Smith E A, Foster S O. et al. Simultaneous administration of smallpox, measles, yellow fever, and diphtheria-pertussis-tetanus antigens to Nigerian children. Bull World Health Organ. 1973;48:175–181. [PMC free article: PMC2481001] [PubMed: 4541683]
112.
Foege W H, Foster S O. Multiple antigen vaccine strategies in developing countries. Am J Trop Med Hyg. 1974;23:685–689. [PubMed: 4847043]
113.
Lane J M, Ruben F L, Neff J M, Millar J D. Complications of smallpox vaccination, 1968. National surveillance in the United States. N Engl J Med. 1969;281:1201–1208. [PubMed: 4186802]
114.
Lane J M, Ruben F L, Neff J M, Millar J D. Complications of smallpox vaccination, 1968: Results of ten statewide surveys. J Infect Dis. 1970;122:303–309. [PubMed: 4396189]
115.
Kempe C H. Studies on smallpox and complications of smallpox vaccination. Pediatrics. 1960;26:176–189. [PubMed: 14408455]
116.
Brainerd H D, Hanna L, Jawetz E. Methisazone in progressive vaccinia. N Engl J Med. 1967;276:620–622. [PubMed: 6018450]
117.
Wilson G.S. The Hazards of Immunization. London, Athlone, 1967.
118.
de Vries E. Post-vaccinal Perivenous Encephalitis. Amsterdam, Elsevier, 1960.
119.
Weber G, Lange J. Zur Variationsbreite der “Inkubationszeiten” postvakzinaler zerebraler Erkrankungen. Dtsch Med Wochenschr. 1961;86:1461–1468. [PubMed: 13783611]
120.
Polak MF. Complications of smallpox vaccination in the Netherlands, 1959–1970. In International Symposium on Smallpox Vaccine. Symposia Series in Immunobiological Standardization 19:235–242, 1973. (pdf)
121.
Berger K, Puntigam F. Uber die Erkrankungshaufigkeit verschiedener Altersklassen von Erstimpflingen an postvakzinaler Enzephalitis nachsubcutaner Pockenschutzimpfung. Wien Med. 1954;104:487–492. [PubMed: 13196333]
122.
Conybeare E T. Illnesses attributed to smallpox vaccination, 1951–1960. Part II. Illnesses reported as affecting the central nervous system. Monthly Bulletin of the Ministry of Health and the Public Health Laboratory Service. 1964;23:150–159. [PubMed: 14201750]
123.
Herrlich A. Probleme der Pocken and Pockenschutzimpfung. Munch Med Wochenschr. 1954;96:529–533. [PubMed: 13165591]
124.
Stuart G. Memorandum on postvaccinal encephalitis. Bull World Health Organ. 1947–1948;1:36–53. [PMC free article: PMC2556141] [PubMed: 20603916]
125.
Femmer J. Cited by Wilson G.S. Hazards of Immunization. London, Athlone, 1967.
126.
Seeleman K. Zerebrale Komplikationen nach Pock-enschutzimpfungen mit besonderer Berucksichtigung der Alterdisposition in Hamburg 1939 bis 1958. Dtsch Med Wochenschr. 1960;85:1081–1089.
127.
van den Berg C A. L'encephalite post-vaccinale aux Pays-Bas. Bull Office Intern Hyg Publique. 1946;38:847–848.
128.
Neff J M, Lane J M. et al. Complications of smallpox vaccination. I. National survey in the United States 1963. N Engl J Med. 1967;276:125–132. [PubMed: 4381041]
129.
Berger K, Heinrich W. Decrease in postvaccinal deaths in Austria after introducing a less pathogenic virus strain. In International Symposium on Smallpox Vaccine. Symposia Series in Immunobiological Standardization 19:199–203, 1973.
130.
Marrenikova SS, Chimishkyan KL, Maltseva NN, et al. Characteristics of virus strains for production of smallpox vaccines. In Proceedings of the Symposium on Smallpox. Zagreb, Yugoslav Academy of Sciences and Arts, 1969, pp 65–79.
131.
Bellows M T, Hyman M R, Merritt K K. et al. Effect of smallpox vaccination on outcome of pregnancy. Public Health Rep. 1949;64:319–323. [PubMed: 18114607]
132.
Abramowitz L J. Vaccination and virus diseases during pregnancy. S Afr Med J. 1957;31:1–3. [PubMed: 13391110]
133.
Bourke G J. Smallpox vaccination in pregnancy; a prospective study. Br Med J. 1964;5397:1544–1546. [PMC free article: PMC1814594] [PubMed: 14133608]
134.
Communicable Disease Center. Manual of Operations: West and Central Africa Smallpox Eradication/Measles Control Program. Atlanta, Centers for Disease Control, 1966.
135.
Tondury G, Foukas M. Die Gefahrdung des menschlichen Keimlings durch Pockenimpfimg in Graviditate. Pathol Microbiol. 1964;27:602–623. [PubMed: 14178198]
136.
Marmelzat W L. Malignant tumors in smallpox vaccination scars. A report of 24 cases. Arch Dermatol. 1968;97:400–406. [PubMed: 4296119]
137.
Sewall S. Vaccinia osteomyelitis. Report of a case with isolation of the vaccinia virus. Bull Hosp Jt Dis. 1949;10:59–63.
138.
Umer J A. Some observations of the vaccination of pregnant women and newborn infants. Am J Obstet Gynecol. 1927;13:70–76.
139.
Lieberman B L. Vaccination of pregnant women and newborn infants. Am J Obstet Gynecol. 1927;14:217–220.
140.
Donnally H H, Nicholson M M. A study of vaccination in five hundred newborn infants. JAMA. 1934;103:1269–1275.
141.
Webster I M. The response of leprosy patients to smallpox vaccine. West Afr Med J. 1959;8:322–324. [PubMed: 13843343]
142.
Browne S G, Davis E M. Reaction in leprosy precipitated by smallpox vaccination. Lepr Rev. 1962;33:252–254. [PubMed: 14016077]
143.
Blake JB. Benjamin Waterhouse and the Introduction of Vaccination; a Reappraisal. Philadelphia, University of Pennsylvania Press, 1957.
144.
Halsey RH. How the President, Thomas Jefferson and Dr. Benjamin Waterhouse established vaccination as a public health procedure. History of Medicine Series No. 5. New York, New York Academy of Medicine, 1936.
145.
Chapin C V, Smith J. Permanency of the mild type of smallpox. J Preventive Med. 1932;6:273–320.
146.
Vaughan V C. Smallpox before and after Edward Jenner. Hygeia. 1923;1:205–211.
147.
Woodward S B, Feemster R F. The relation of smallpox morbidity to vaccination laws. N Engl J Med. 1933;208:317–318.
148.
Leake J P. Questions and answers on smallpox vaccination. Public Health Rep. 1927;42:221–238.
149.
Low RB. The Incidence of Small-pox Throughout the World in Recent Years. Reports to the Local Government Board on Public Health and Medical Subjects NS No. 117. London, His Majesty's Stationery Office, 1918.
150.
Henneberg G. The distribution of smallpox in Europe 1919–1948. In Rodenwaldt E, Jusatz HJ (eds). World-Atlas of Epidemic Diseases, Part II. Hamburg, Falk-Verlag, 1956, pp 67–72.
151.
Rodrigues B A. Smallpox eradication in the Americas. Bull Pan Am Health Organ. 1975;9:53–68. [PubMed: 167890]
152.
Arita I, Henderson DA. Freeze-dried vaccine for the smallpox eradication programme. In Proceedings of the Symposium on Smallpox. Zagreb, Yugoslav Academy of Sciences and Arts, 1969, pp 39–50.
153.
Arita I. The control of vaccine quality in the smallpox eradication programme. In International Symposium on Smallpox Vaccine. Symposia Series in Immunobiological Standardization 19:79–87, 1973.
154.
Henderson DA, Arita I, Shafa E. Studies of the bifurcated needle and recommendations for its use. Unpublished document. Geneva, World Health Organization, 1969.
155.
Mack T M, Thomas D B, Ali A, Khan M M. Epidemiology of smallpox in West Pakistan. 1. Acquired immunity and the distribution of disease. Am J Epidemiol. 1972;95:157–168. [PubMed: 5060373]
156.
Foege W H, Millar J D, Lane J M. Selective epidemiologic control in smallpox eradication. Am J Epidemiol. 1971;94:311–315. [PubMed: 5110547]
157.
World Health Organization. Report of the WHO Ad Hoc Committee on Orthopoxvirus Infections. Wkly Epidemiol Rec 6:289, 1986.
158.
Mahy B W J, Almond J W, Bems K I. et al. The remaining stocks of smallpox virus should be destroyed. Science. 1993;262:1223–1224. [PubMed: 8235651]
159.
Roizman B, Joklik W, Fields B, Moss B. The destruction of smallpox virus stocks in national repositories: A grave mistake and a bad precedent. Infect Agents Dis. 1994;3:215–217. [PubMed: 7866654]
160.
World Health Organization. Report of the Ad Hoc Committee on Orthopoxvirus Infections. Executive Board Report EB 95/33 dated October 10, 1994.
161.
Mackett M, Smith G L, Moss B. Vaccinia virus: A selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA. 1982;79:7415–7419. [PMC free article: PMC347350] [PubMed: 6296831]
162.
Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA. 1982;79:4927–4931. [PMC free article: PMC346798] [PubMed: 6289324]
163.
Smith G L, Moss B. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene. 1983;25:21–28. [PubMed: 6229451]
164.
Perkus M E, Piccini A, Lipinskas B R, Paoletti E. Recombinant vaccinia virus: Immunization against multiple pathogens. Science. 1985;229:981–984. [PubMed: 2992092]
165.
Moss B. Vaccinia virus: A tool for research and vaccine development. Science. 1991;252:1662–1667. [PubMed: 2047875]
166.
Fenner F, Comben B M. Genetic studies with mammalian poxviruses. I. Demonstration of recombination between two strains of poxviruses. Virology. 1958;5:530–548. [PubMed: 13557735]
167.
Sam C K, Dumbell K R. Expression of poxvirus DNA in coinfected cells and marker rescue of thermosensitive mutants by subgenomic fragments of DNA. Ann Viral. 1981;132E:135–150.
168.
Nakano E, Panicali D, Paoletti E. Molecular genetics of vaccinia virus: Demonstration of marker rescue. Proc Natl Acad Sci USA. 1982;79:1593–1596. [PMC free article: PMC346021] [PubMed: 6951197]
169.
Weir J P, Bajszar G, Moss B. Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA. Proc Natl Acad Sci USA. 1982;79:1210–1214. [PMC free article: PMC345931] [PubMed: 6280173]
170.
Mackett M, Smith G L, Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol. 1984;49:857–864. [PMC free article: PMC255547] [PubMed: 6321770]
171.
Earl PL, Moss B. Generation of recombinant vaccinia viruses. In Ausubel FM, Brent R, Kingston RE, et al (eds). Current Protocols in Molecular Biology. New York, Greene Publishing Associates & Wiley Interscience, 1991, pp 16.17.11–16.17.16.
172.
Davison A J, Moss B. The structure of vaccinia virus early promoters. J Mol Biol. 1989;210:749–769. [PubMed: 2515286]
173.
Davison A J, Moss B. The structure of vaccinia virus late promoters. J Mol Biol. 1989;210:771–784. [PubMed: 2515287]
174.
Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA. 1996;93:11341–11348. [PMC free article: PMC38059] [PubMed: 8876137]
175.
Fenner F, Henderson DA, Arita I, et al. Smallpox and Its Eradication. Geneva, World Health Organization, 1988.
176.
Cooney E L, Collier A C, Greenberg P D. et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet. 1991;337:567–572. [PubMed: 1671940]
177.
Buller R M L, Smith G L, Cremer K. et al. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature. 1985;317:813–815. [PubMed: 4058585]
178.
Lee S L, Roos J M, McGuigan L C. et al. Molecular attenuation of vaccinia virus: Mutant generation and animal characterization. J Virol. 1992;66:2617–2630. [PMC free article: PMC241015] [PubMed: 1560521]
179.
Buller R M L, Palumbo G J. Poxvirus pathogenesis. Microbiol Rev. 1991;55:80–122. [PMC free article: PMC372802] [PubMed: 1851533]
180.
Tartaglia J, Perkus M E, Taylor J. et al. NYVAC-a highly attenuated strain of vaccinia virus. Virology. 1992;188:217–232. [PubMed: 1566575]
181.
Konishi E, Pincus S, Paoletti E. et al. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NSl genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology. 1992;190:454–458. [PubMed: 1326813]
182.
Stephenson C B, Welter J, Thaker S R. et al. Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC and ALVAC-based CDV recombinants protect against symptomatic infection. J Virol. 1997;71:1506–1513. [PMC free article: PMC191207] [PubMed: 8995676]
183.
Mayr A, Hochstein-Mintzel V, Stickl H. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-stammes MVA. Infection. 1975;3:6–14.
184.
Sticl H, Hochstein-Mintzel V, Mayr A. et al. MVA-Stufenimpfung gegen Pocken. Klinische Erprobung des attenuierten Pocken-lebendimpfstoffes, Stamm MVA. Dtsch Med Wochenschr. 1974;99:2386–2392. [PubMed: 4426258]
185.
Sutter G, Moss B. Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA. 1992;89:10847–10851. [PMC free article: PMC50439] [PubMed: 1438287]
186.
Sutter G, Wyatt L S, Foley P L. et al. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine. 1994;12:1032–1040. [PubMed: 7975844]
187.
Hirsch V M, Fuerst T R, Sutter G. et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol. 1996;70:3741–3752. [PMC free article: PMC190250] [PubMed: 8648709]
188.
Wyatt L S, Shors S T, Murphy B R, Moss B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine. 1996;14:1451–1458. [PubMed: 8994321]
189.
Bennink J R, Yewdell J W, Smith J W. et al. Recombinant vaccinia virus primes and stimulates influenza virus HA-specific CTL. Nature. 1984;311:578–579. [PubMed: 6332992]
190.
Yewdell J W, Bennink J R, Smith G L, Moss B. Influenza A virus nucleoprotein is a major target for cross-reactive anti-influenza virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA. 1985;82:1785–1789. [PMC free article: PMC397357] [PubMed: 3872457]
191.
Walker B D, Chakrabarti S, Moss B. et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987;328:345–348. [PubMed: 3496541]
192.
Walker B D, Flexner C, Paradis T J. et al. HIV-1 reverse transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science. 1988;240:64–66. [PubMed: 2451288]
193.
Bennink J R, Yewdell J W. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr Top Microbiol Immunol. 1990;163:153–184. [PubMed: 2242679]
194.
Otteken A, Earl P L, Moss B. et al. Folding, assembly, and intracellular trafficking of the human immunodeficiency virus type 1 envelope glycoprotein analyzed with monoclonal antibodies recognizing maturational intermediates. J Virol. 1996;70:3407–3415. [PMC free article: PMC190213] [PubMed: 8648672]
195.
Olmsted R A, Elango N, Prince G A. et al. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: Comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci USA. 1986;83:7462–7466. [PMC free article: PMC386738] [PubMed: 3532115]
196.
Spriggs M K, Murphy B R, Prince G A. et al. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: Contributions of the individual proteins to host immunity. J Virol. 1987;61:3416–3423. [PMC free article: PMC255937] [PubMed: 2822951]
197.
Paterson R G, Lamb R A, Moss B, Murphy B R. Comparison of the relative roles of the F and HN surface glycoproteins of the paramyxovirus simian virus 5 in inducing protective immunity. J Virol. 1987;61:1972–1977. [PMC free article: PMC254205] [PubMed: 3573154]
198.
Connors M, Kulkarni A B, Collins P L. et al. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (VacM2) is mediated by CD8+ T cells, while that induced by Vac-F or Vat-G recombinants is mediated by antibodies. J Virol. 1992;66:1277–1281. [PMC free article: PMC240842] [PubMed: 1731105]
199.
Andrew M E, Coupar B E H, Boyle D B, Ada G L. The roles of influenza virus haemagglutinin and nucleoprotein as protective antigens against influenza virus infection in mice. Scand J Immunol. 1987;25:21–28. [PubMed: 3492756]
200.
Moss B, Smith G L, Gerin J L, Purcell R H. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature. 1984;311:67–69. [PubMed: 6472464]
201.
Flexner C, Moss B. New generation vaccines. In Levine MM, Woodrow GC, Kasper JB, Cobon GS (eds). New Generation Vaccines. New York, Marcel Dekker, 1997, pp 297–314.
202.
Bemards R, Destree A, McKenzie S. et al. Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA. 1987;84:6854–6858. [PMC free article: PMC299183] [PubMed: 3477812]
203.
Estin C D, Stevenson U S, Plowman G D. et al. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Proc Natl Acad Sci USA. 1988;85:1052–1056. [PMC free article: PMC279699] [PubMed: 3422478]
204.
Kantor J, Irvine K, Abrams S. et al. Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res. 1992;52:6917–6925. [PubMed: 1458480]
205.
Carroll M W, Overwiijk W W, Chamberlain R S. et al. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: A murine tumor model. Vaccine. 1997;15:387–394. [PMC free article: PMC1950787] [PubMed: 9141209]
206.
Bovle D B, Counar B E H. Construction of recombinant fowlpox viruses as vectors for poultry vaccines. Virus Res. 1988;10:343–356. [PubMed: 2842977]
207.
Romero C H, Barrett T, Evans S A. et al. Single capripoxvirus recombinant vaccine for the protection of cattle against rinder pest and lumpy skin disease. Vaccine. 1993;11:737–742. [PubMed: 8342321]
208.
Taylor J, Weinberg R, Languet B. et al. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine. 1988;6:497–503. [PubMed: 2854338]
209.
Somogyi P, Frazier J, Skinner M A. Fowlpox virus host range restriction: Gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology. 1993;197:439–444. [PubMed: 8212580]
210.
Langford D J, Edwards S J, Smith G L. et al. Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus infected cells increases its immunogenicity. Mol Cell Biol. 1986;6:3191–3199. [PMC free article: PMC367055] [PubMed: 3537732]
211.
Both G W, Andrew M E, Boyle D B. et al. Relocation of antigens to the cell surface membrane can enhance immune stimulation and protection. Immunol Cell Biol. 1992;70:73–78. [PubMed: 1322362]
212.
Ramsay A J, Ramsay A J, Leong K H. et al. Vector-encoded interleukin-5 and interleukin-6 enhance specific mucosal immunoglobulin A reactivity in vivo. Adv Exp Med Biol. 1995;317A:35–42. [PubMed: 8525942]
213.
Chamberlain R S, Carroll M W, Bronte V. et al. Costimulation enhances the active immunotherapy effect of recombinant anti-cancer vaccines. Cancer Res. 1996;56:2832–2836. [PMC free article: PMC2248455] [PubMed: 8665522]
214.
Bronte V, Tsung K, Rao J B. et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol. 1995;154:5282–5292. [PMC free article: PMC2041892] [PubMed: 7730632]
215.
Hekker A C, Bos J M, Smith L. A stable freeze-dried smallpox vaccine made in monolayer cultures of primary rabbit kidney cells. J Biol Stand. 1973;1:21–32.
216.
Graham B S, Belshe R B, Clements M L. et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type-1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis. 1992;166:244–252. [PubMed: 1353102]
217.
Earl P L, Hugin A W, Moss B. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J Virol. 1990;64:2448–2451. [PMC free article: PMC249414] [PubMed: 2182912]
218.
Cooney E L, McElrath M J, Corey L. et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160-protein. Proc Natl Acad Sci USA. 1993;90:1882–1886. [PMC free article: PMC45984] [PubMed: 8446603]
219.
Graham B S, Matthews T J, Belshe R B. et al. Augmentation of human immunodeficiency virus type-l neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgpl60 in vaccinia-naive adults. J Infect Dis. 1993;167:533–537. [PubMed: 8095059]
220.
Pialoux G, Excler J L, Riviere Y. et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses. 1995;11:373–381. [PubMed: 7598771]
221.
Egan M, Ravlat W, Tartaglia J. et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a non-replicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1 MN env gene. J Infect Dis. 1995;171:1623–1627. [PubMed: 7769304]
222.
Fleury B, Janvier G, Pialoux G. et al. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-l)-negative volunteers immunized with a recombinant canarypox expressing gp160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis. 1996;174:734–738. [PubMed: 8843210]
223.
Gu S Y, Huang T M, Ruan L. et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand. 1995;84:171–177. [PubMed: 7796951]
224.
Cadoz M, Strady A, Meignier B. et al. Immunization with canarypox virus expressing rabies glycoprotein. Lancet. 1992;339:1429–1432. [PubMed: 1351126]
225.
Fries L F, Tartaglia J, Taylor J. et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system. Vaccine. 1996;14:428–434. [PubMed: 8735555]
226.
Fenner F, Gibbs EPJ, Murphy FA, et al. Veterinary Virology (2nd ed). San Diego, CA, Academic Press, 1993.
227.
Mackett M, Yilma T, Rose J K, Moss B. Vaccinia virus recombinants: Expression of VSV genes and protective immunization of mice and cattle. Science. 1985;227:433–435. [PubMed: 2981435]
228.
Giavedoni L, Jones L, Mebus C, Yilma T. A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions. Proc Natl Acad Sci USA. 1991;88:8011–8015. [PMC free article: PMC52435] [PubMed: 1896447]
229.
Brockmeier S L, Lager K M, Tartaglia J. et al. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses. Vet Microbiol. 1993;38:41–58. [PubMed: 8128602]
230.
Chambers T M, Kawaoka Y, Webster R G. Protection of chickens from lethal influenza infection by vaccinia-expressed hemagglutinin. Virology. 1988;167:414–421. [PubMed: 3264429]
231.
Wiktor T J, Macfarlan R I, Reagan K J. et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci USA. 1984;81:7194–7198. [PMC free article: PMC392104] [PubMed: 6095272]
232.
Rupprecht C E, Wiktor T J A, Johnston D H. et al. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci USA. 1986;83:7947–7950. [PMC free article: PMC386841] [PubMed: 3464010]
233.
Brochier B, Costy F, Pastoret P P. Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies vaccine: An update. Vet Microbiol. 1995;46:269–279. [PubMed: 8545965]
234.
Esposito J J, Knight J C, Shaddock J H. et al. Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virology. 1988;165:313–316. [PubMed: 3291388]
235.
Romero C H, Barrett T, Chamberlain R W. et al. Recombinant capripoxvirus expressing the hernagglutinin protein gene of rinderpest virus: Protection of cattle against rinderpest and lumpy skin disease. Virology. 1994;204:425–429. [PubMed: 8091673]
236.
van der Leek M L, Feller J A, Sorenson G. et al. Evaluation of swinepox virus as a vaccine vector in pigs using an Aujeszky's disease (pseudorabies) virus gene insert coding for glycoproteins gp50 and gp63. Vet Rec. 1994;134:13–18. [PubMed: 8128561]
237.
Webster R G, Kawaoka Y, Taylor J. et al. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine. 1991;9:303–308. [PubMed: 1651609]
238.
Boursnell M E, Green P F, Samson A C. et al. A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV. Virology. 1990;178:297–300. [PubMed: 2167557]
239.
Edbauer C, Weinberg R, Taylor J. et al. Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin-neuraminidase gene. Virology. 1990;179:901–904. [PubMed: 2173266]
240.
Bayliss C D, Peters R W, Cook J K A. et al. A recombinant fowlpox virus that expresses the VP2 antigen of infectious bursal disease virus induces protection against mortality caused by the virus. Arch Virol. 1991;120:193–205. [PubMed: 1659797]
241.
Tartaglia J, Jarrett O, Neil J C. et al. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol. 1993;67:2370–2375. [PMC free article: PMC240401] [PubMed: 8383248]
Copyright © 1999, W.B. Saunders Company.
Bookshelf ID: NBK7296

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...